Generic placeholder image

Current Cardiology Reviews


ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Review Article (Mini-Review)

Cardiac MRI in Autoimmune Diseases: Where Are We Now?

Author(s): Natalia G. Vallianou*, Eleni Geladari, Fotis Panagopoulos and Maria Kalantzi

Volume 17 , Issue 5 , 2021

Published on: 08 January, 2021

Article ID: e160721190002 Pages: 6

DOI: 10.2174/1573403X16666210108104236

Price: $65


Cardiovascular magnetic resonance imaging (CMR) allows the early diagnosis of various cardiovascular pathophysiologic phenomena in autoimmune diseases. Preliminary studies suggest that CMR holds a promising role in initiating the necessary changes in anti-rheumatic and cardiac treatment among patients with autoimmune diseases and cardiovascular diseases (CVD). It is widely known that the presence of late gadolinium enhancement (LGE) has been related to a worse cardiovascular prognosis. CMR has been documented to be the most valuable tool for diagnosis and risk prediction of cardiac involvement in a sarcoidosis population, while in SLE, the gap between clinical and autopsy diagnosis of the myocardial disease could be narrowed with the implementation of CMR. In different connective tissue diseases, including SLE, LGE has been demonstrated to be present early after the initial diagnosis of SLE. Considering that CMR, including LGE identifies more patients with silent myocardial disease in SLE and other connective tissue diseases than echocardiography, CMR should be the preferred imaging modality, especially in the era of modern techniques with broader availability and expertise. In this review, we summarize the major indications, advantages and limitations of the use of CMR among patients with autoimmune disorders.

Keywords: Autoimmune disorders, cardiac magnetic resonance (CMR), late gadolinium enhancement (LGE), early gadolinium enhancement (EGE), cardiac MRI, EGPA.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy